Molecular profiles

screening of new anti-cancer agents

In the era of personalized medicine, GLIOscreen drug screening service can serve to identify (subgroups of) glioma patients that will benefit from specific treatments. Stratification of patients in phase II/III clinical studies according to predicted response may increase the probability of demonstrating therapeutic activity of novel agents or treatment regimens. Molecular data (RNA/DNA) of parental tumors can be analyzed in the context of response to a specific treatment, allowing the identification of (a set of) genes that predict response  (“predictor profiles”).